Suchergebnisse - "Gupta, Neeraj"

PubPharm (10)

1

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

enthalten in: British journal of haematology | 2019

von Kumar, S. | Grzasko, N. | Delimpasi, S. | +9

2

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Dimopoulos, M. | Grosicki, S. | Jędrzejczak, W. | +10

3

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Dimopoulos, M. | Gay, F. | Schjesvold, F. | +124

CommentIn: Lancet. 2019 Jan 19;393(10168):204-205. - PMID 30545778

4

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

enthalten in: Haematologica | 2018

von San-Miguel, J. | Echeveste Gutierrez, M. | Špicka, I. | +13

5

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma

enthalten in: British journal of haematology | 2018

von Richardson, P. | Hofmeister, C. | Rosenbaum, C. | +15

6

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

enthalten in: British journal of haematology | 2017

von Kumar, S. | Moreau, P. | Hari, P. | +17

7

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

enthalten in: Blood | 2017

von Sanchorawala, V. | Palladini, G. | Kukreti, V. | +12

ErratumIn: Blood. 2020 Mar 26;135(13):1071. - PMID 32219354

8

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis

enthalten in: British journal of haematology | 2016

von Gupta, N. | Hanley, M. | Harvey, R. | +10

9

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

enthalten in: Investigational new drugs | 2015

von Smith, D. | Kalebic, T. | Infante, J. | +14

10

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

enthalten in: Blood | 2014

von Richardson, P. | Baz, R. | Wang, M. | +11

CommentIn: Blood. 2014 Aug 14;124(7):986-7. - PMID 25124778

1
[1]